- i) Systems/methods for the preparation of PRP and HA in a single "all in one" device – the CELLULAR MATRIX™ technology* with tubes containing HA, a thixotropic gel and an anticoagulant: U.S. Patent No. 10,272,139 and ii) Systems for the preparation of thrombin serum and biological glue, in particular tubes containing a thixotropic gel: U.S. Patent No. 10,226,516. These new patents represent a recognition by the USPTO of RegenLab's innovation, technology and efficiency. This is great news for RegenLab, its employees and partners, and justifies RegenLab's investment in R&D and enforcement of its intellectual property rights. This brings a total of 10 (ten) U.S. granted patents on these technologies, expanding RegenLab's patent portfolio along with patents also recently granted in other jurisdictions: i) Methods for the preparation of PRP by centrifuging tubes with a (polymeric) thixotropic gel (+ anticoagulant) and removing Platelet Poor Plasma (PPP), optionally combined with a cell extract or coagulation activator: US10,092,598 ii) Methods for the preparation of PRP by centrifuging tubes with only a thixotropic gel and anticoagulant, optionally combined with e.g. a coagulation activator, a cell extract, cream, filler, hydrogel, vitamin, antalgic, analgesic or HA: US10,080,770 iii) Systems for the preparation of PRP and Bone Marrow Concentrate (BMC), in particular tubes containing a thixotropic gel and anticoagulant: US10,064,894 iv) Systems/methods combining PRP and HA in two separate devices: US10,052,349 v) Systems/methods for the preparation of PRP, in particular tubes containing a thixotropic gel and sodium citrate as anticoagulant: US9,833,478 vi) Composition comprising HA, anticoagulant and thixotropic gel, tube/container containing such composition, combination with coagulation activator or cell extract: US9,517,255 vii) Methods for the preparation of HA and PRP in a single device, in particular centrifuging tubes containing HA and optionally a gel and anticoagulant, optionally combined with e.g. a coagulation activator or cell extract: US8,945,537 viii) Specific PRP compositions, tubes containing specific thixotropic gels and anticoagulants, combination with cell extracts, related methods and cell culture methods: US8,529,957. *PRP : Platelet Rich Plasma *HA : Hyaluronic Acid *ATS : Autologous Thrombin SerumCN105998067 US2018327120 and EP2771241 About RegenLab RegenLab is a leading innovator of medical devices for the preparation of platelet rich plasma, which it markets under the well-recognized REGENLAB®, REGENKIT® and CELLULAR MATRIX™* brands. RegenLab remains committed to providing pyrogen-free devices of the highest quality and safety, as well as protecting customers through enforcement of its intellectual property rights. Additional information about RegenLab and its patents can be found at https://www.regenlab.com/corporate/ patents and https://www.regenlabusa.com. *Only available for research purposes in the United States (not available for sale) RegenLab® USA LLC 575 Madison AvenueSuite 1006 New York, NY 10022-2511 Phone & Fax: 1-800-220-9082www.regenlabusa.com Regen Lab SA En Budron B2CH - 1052 Le Mont-Sur-LausanneSwitzerland Tel. +41(0)21 864 01.11 Fax. +41(0)21 864 01.10www.regenlab.com Roberta Ruggeri, Tel. +41(0)21 864 01.11 https://mma.prnewswire.com/media/890782/Patent_document_Infographic.jpghttps://mma.prnewswire.com/media/890783/Patent_document_Infographic.jpghttps://mma.prnewswire.com/media/890784/Patent_certificate_Infographic.jpgLogo - https://mma.prnewswire.com/media/890785/Regen_Lab_SA_Logo.jpg